Atopic dermatitis

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy

Retrieved on: 
火曜日, 4月 16, 2024
ILC2, FDA, Idiopathic pulmonary fibrosis, Irritation, Blister, Hope, Safety, T helper cell, Animal, SAE, Research, JAK1, Immunoglobulin G, Therapy, Patient, EAACI, Clinical trial, Atopic dermatitis, Asthma, Immunity, FIC, Pharmaceutical industry

The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.

Key Points: 
  • The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.
  • The Allergy article and the results of the US Phase I study scientifically validated the favourable efficacies and good safety profile of SM17 for treating AD.
  • We are pleased that evidence demonstrating the advantageous therapeutic potential of SM17 for treating AD is scientifically confirmed and endorsed by being published on the renowned peer-reviewed journal Allergy.
  • The preclinical results will be confirmed in human in a proof of concept clinical trial in AD patients that was initiated in April 2024."

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Retrieved on: 
木曜日, 5月 9, 2024
Biotechnology, Pharmaceutical, Health, Society, Investment, Attack, Safety, CST, Poster, CSR, Research, Biophysical environment, OX40, IND, Pharmacology, YTE, Hereditary angioedema, Patient, Allergy, ESG, Corporate social responsibility, Plasma kallikrein, HAE, Therapy, Atopic dermatitis, Investigational New Drug, Session One, Pharmaceutical industry

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
  • The trial saw a 92-100% decrease in moderate or severe attacks and a 91-95% reduction in attacks requiring rescue medications with STAR-0215.
  • Based on the positive results from the ALPHA-STAR trial, Astria plans to advance STAR-0215 to Phase 3 development.
  • The 2023 report provides a comprehensive update on the Company’s performance and progress across key Environmental, Social, and Governance (ESG) areas of focus.

Global Skin Allergy Testing Market Expected to Reach $771.5 Million by 2028

Retrieved on: 
木曜日, 5月 9, 2024
Education, Dermatitis, Asthma, Hospital, Allergy, Allergic conjunctivitis, Drug allergy, Allergen, Automation, Food, Incidence, Diagnosis, BCC, Health, Allergic rhinitis, Atopic dermatitis, Skin, Growth, Prevalence

BOSTON, May 9, 2024 /PRNewswire/ -- "According to the latest BCC Research study, the demand for Global Skin Allergy Testing Market is expected to grow from $560 million in 2023 and is projected to reach $771.5 million by the end of 2028, at a compound annual growth rate (CAGR) of 6.6% during the forecast period."

Key Points: 
  • The report provides an in-depth overview of the global skin allergy testing market and provides comprehensive insights into its dynamics and future trajectory till 2028.
  • The skin prick test segment largely dominates the skin allergy testing market as it is widely used as the primary method of allergy testing.
  • Furthermore, the integration of automation in skin prick testing, fueled by technological advancements, may revolutionize the skin allergy testing landscape and is expected to drive significant market development soon.
  • These joint efforts are helping to expand the global skin allergy testing market.

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
木曜日, 5月 9, 2024
American Academy, Ulcerative colitis, BDCA2, American Association of Immunologists, CDAI, American Academy of Dermatology, PD-1, IND, Week, AAI, Therapy, Patient, Graft-versus-host disease, Rheumatoid arthritis, AAD, Atopic dermatitis, BTLA, SAN, UC, Pharmaceutical industry

“This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.

Key Points: 
  • “This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.
  • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023.
  • Research and development expenses were $37.0 million for the three months ended March 31, 2024, compared to $35.0 million for the three months ended March 31, 2023.
  • General and administrative expenses were $12.3 million for the three months ended March 31, 2024, compared to $10.8 million for the three months ended March 31, 2023.

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 5月 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives

Retrieved on: 
木曜日, 5月 9, 2024
Tao, Inflammation, Therapy, IL13, Patient, Venture round, Atopic dermatitis, Pharmaceutical industry

FREMONT, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised by the Company since its launch in June 2023 to $165 million. Proceeds from the financing will be used to advance the Company’s lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Company’s immunology and inflammation pipeline, and to further develop the ATTOBODY™ platform.

Key Points: 
  • The Series B financing was led by Goldman Sachs Alternatives, with participation from new investors Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, and Logos Capital.
  • Concurrent with the financing, Colin Walsh, Ph.D., Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, was appointed to the Company’s Board of Directors.
  • Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025.
  • The Company is also developing discovery stage programs that expand the ATTOBODY platform footprint to novel, difficult-to-drug targets, and offer additional multi-specific combinations.

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Phase 10, Research, Consultant, Patient, Liver failure, Inflammation, Clinical trial, Atopic dermatitis, Therapy, Asthma, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.
  • Concurrently, we are continuing our investigation and analysis of the serious adverse event that triggered the clinical hold.”
    Financial Results for the First Quarter March 31, 2024
    First Quarter Ended March 31, 2024
    Net loss for the first quarter of 2024 was $30.5 million, compared to $29.3 million for the first quarter of 2023.
  • Research and development expenses for the first quarter of 2024 were $24.8 million, compared to $25.6 million for the same period in 2023.
  • General and administrative expenses for the first quarter of 2024 were $7.7 million, compared to $6.0 million for the same period in 2023.

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Retrieved on: 
火曜日, 5月 7, 2024
Pancreatic cancer, ITK, Hidradenitis suppurativa, Research, ACRS, Webcast, Patient, Rheumatoid arthritis, Lilly, Interim, Atopic dermatitis, Therapy, G&A, Pharmaceutical industry

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.
  • In September 2023, Aclaris reported positive results from its Phase 1 multiple ascending dose (MAD) trial of ATI-2138.
  • Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023.
  • Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023.

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

Retrieved on: 
火曜日, 5月 7, 2024
Chicago Medical School, Itch, University, Patient, Skin, MD, Doctor of Philosophy, KOL, Potential, Week, Data, University of Rochester, Physician, Magnetic resonance, Atopic dermatitis, ASLN, Clutch (eggs), SAN, Pharmaceutical industry

“The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.

Key Points: 
  • “The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.
  • During the KOL event today, Company management will present new data on investigator-assessed and patient-reported secondary endpoints and data from the subgroup of patients with prior inadequate response to dupilumab.
  • Discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo (43%, 3/7).
  • Waterfall plots of individual patient responses show clear and consistent improvements in almost all patients treated with eblasakimab versus placebo.

AAFA Co-Hosts Congressional Briefing Highlighting 25th Year of National Asthma Control Program

Retrieved on: 
火曜日, 5月 7, 2024
Mortality, Public, Climate change, United, Allergist, Risk, CDC, Health, Pollen, Congress, NACP, Dingell, AAFA, Public policy, Food, Air pollution, Legislation, World Asthma Day, Anaphylaxis, Alaska Natives, Allergy, Atopic dermatitis, Quality of life, Polyp (medicine), Eosinophilic esophagitis, COVID-19, Calendar, RSV, Pharmaceutical industry

Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.

Key Points: 
  • Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.
  • “The NACP provides resources for asthma education that help empower people with asthma,” said Kenneth Mendez, president and CEO of AAFA.
  • And for every $1 spent, the NACP saves $71 in total economic costs related to asthma.
  • On behalf of the 27 million people in the US with asthma, we’re grateful for the positive impact NACP has made over the past 25 years.